Taiwan Temporarily Stops Administration of Second Dose Pfizer-BioNTech Vaccine in 12 to 17-year-old Cohort to Evaluate Safety Situation

Taiwan Temporarily Stops Administration of Second Dose Pfizer-BioNTech Vaccine in 12 to 17-year-old Cohort to Evaluate Safety Situation

Known as the Republic of China or, more commonly, Taiwan, this island nation formed after the communist revolution on the Chinese mainland has, for the most part, avoided much of the pandemic except for a huge Delta variant-driven surge during the spring of 2021. With approximately 23.5 million people, the island has recorded approximately 16,400 cases of SARS-CoV-2 with 848 deaths. Recently Chen Shih-chung, the leader of their Central Epidemic Command Center (CECC), reported that a panel of experts opted to suspend the administration of the second dose of the Pfizer-BioNTech COVID-19 vaccine known as BN2162b2 to young people aged 12 to 17-years-old due to growing concerns of the heightened risk of myocarditis.

As reported recently in Taiwan News, health regulators here are increasingly concerned about the safety associated with the mRNA-based vaccine. The Taiwanese report authored by George Liao referred to mounting U.S. safety statistics indicating growing heart muscle inflammation risk to youth post the second Pfizer-BioNTech jab—in some cases as much as 10X higher the risk when compared to the first dose.

TrialSite has reported much of Scandinavia has changed p...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

Personal
$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
Professional
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee